Latest News about GILD
Recent news which mentions GILD
Is Gilead Sciences Stock a Buy Now?
December 07, 2021
From Motley Fool
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
December 07, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
From Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
From Benzinga
December SPAC Merger Calendar: Upcoming Votes, Stocks To Watch
December 05, 2021
From Benzinga
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
From Motley Fool
3 Reasons Pfizer Stock Will Crush the Broader Market in 2022
December 01, 2021
From Motley Fool
From MarketWatch
Why NRx Pharmaceuticals Stock Soared Today
November 29, 2021
From Motley Fool
Why Are NRx Pharma's Shares Soaring Premarket?
November 29, 2021
From Benzinga
3 Dividend Stocks That Are Dirt Cheap Right Now
November 25, 2021
From Motley Fool
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
November 24, 2021
From Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
From Benzinga
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
From Motley Fool
Better Buy: Vertex Pharmaceuticals vs. CRISPR
November 20, 2021
From Motley Fool
Is Merck Stock a Buy?
November 20, 2021
From Motley Fool
Why Are Arcus Biosciences Shares Trading Higher Today?
November 18, 2021
From Benzinga
Why Arcus Biosciences Stock Is On Fire Today
November 18, 2021
From Motley Fool
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
November 15, 2021
From Motley Fool
On Target: This Company Says It Delivers Drugs Exactly How You Need Them
November 15, 2021
From Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
From Benzinga
Better COVID Stock: Merck vs. Pfizer
November 09, 2021
From Motley Fool
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
November 05, 2021
From Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
From Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.